TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. - Wikidata - wikimedia - TriplyDB

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

http://www.wikidata.org/entity/Q34785862

about

The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background The Natural Course of Non-Alcoholic Fatty Liver Disease Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease Genetic background in nonalcoholic fatty liver disease: A comprehensive review Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis Nonalcoholic fatty liver disease: new treatments Molecular Pathogenesis of NASH How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease?Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.Recent advances in understanding/management of non-alcoholic steatohepatitis.Metabolism Disrupting Chemicals and Metabolic Disorders Genetic predisposition in nonalcoholic fatty liver disease.Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics.Non-alcoholic fatty liver disease: An expanded review The Association between Pediatric NAFLD and Common Genetic Variants.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins.TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study.Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity.Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan DNA methylation profiling identifies novel markers of progression in hepatitis B-related chronic liver disease.Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population.Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review.Is Hepatocellular Cancer the Same Disease in Alcoholic and Nonalcoholic Fatty Liver Diseases?Functional annotation of sixty-five type-2 diabetes risk SNPs and its application in risk prediction Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.Hepatic Tm6sf2 overexpression affects cellular ApoB-trafficking, plasma lipid levels, hepatic steatosis and atherosclerosis.TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review.Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era.

P2860

Q26744380-342B7F57-2504-4FC7-AB7F-8ACDC4C2F742 Q26746947-5C7CD33E-AFF1-4DF3-B901-178D995C7BD5 Q26764911-7EB0E83B-167B-4B22-B8D3-159AD178EA0C Q26765455-6A01B229-97A5-4055-9699-226E04AC0DF2 Q26774883-2C2A42FA-1B28-4728-B428-14DE74517260 Q26780248-58BEF5BA-C769-458D-A90F-59FB9830174C Q26798151-893CD286-2127-45FC-B86B-DFB8D862903E Q27021161-772AF86A-AF9B-4AB5-A9CD-42221E8C2C79 Q28071265-B9EE9C40-58B6-4B63-BC02-4121BD7E445D Q28074455-B804455A-4D6D-494D-8757-F62BF244D6E3 Q28082686-398F41D9-54FA-4DEC-BAE8-1FF4EA9541D8 Q28085689-4300449A-352A-4AFF-8C87-2BFF5D9A0045 Q29248099-931CBEB6-F576-4F0E-92B1-342A07BDF863 Q30235398-783EC235-1D12-43BB-8E3A-BDFD6D451841 Q30732041-2CDE19C2-AAA3-433F-B492-D85A27287B93 Q33360950-8CB6A2AA-7942-4F5A-919B-BE90769F33B1 Q33789868-4A78F137-9F5E-48CB-967B-CD9815CFB9EA Q33831722-A899E014-2EAE-4BF2-8AA0-F2B7DB592651 Q33866766-0DD5F6CF-83A8-4880-8379-691D3A1E1008 Q34519771-DBD0A9EC-85C1-48EA-AF4E-B3579537B964 Q34677873-59C6A0D1-3AF0-40A9-8C31-23B9DA127DC8 Q35914994-A3A27EF5-F083-441C-9C58-A48D85F7294E Q35948098-005B329F-FC1D-4836-9FE7-B55DE4F5190C Q36129673-D43D7841-1F4B-458E-8231-593139764A2D Q36140409-1DE8FAC3-0638-44C6-BC99-7F788AAE3549 Q36396108-B06A65FA-DEBE-4F2A-AB21-A4C274946C59 Q36828380-30058C9D-3612-4B87-8BBE-5E7E445313C1 Q36833028-7A9775D3-6F0D-4265-BE9F-C7DECD43C902 Q36848963-0C9C1855-D983-490E-B117-C59CD42BC71B Q36871793-B2FF2A50-5A16-418B-9BF2-13B43FA818A8 Q37088653-F0EEEAD4-8083-4A1F-BE7D-0864140F6BE0 Q37143687-BB54CA68-1D17-4D6A-9BC9-CB675D95D949 Q37146192-16207FCE-0660-4DC6-A540-B49CA0A772ED Q37432586-9DA0E4A7-17EE-4229-B841-59F2F5CBDE54 Q37681763-250C9426-9313-44B8-99A8-A53B641A1F3F Q38802973-7867DAFB-35A2-4E61-B85B-CAD6914545F1 Q38816682-6FDF0FE1-98B8-4403-85EC-A3C27D70EA5A Q39062036-B8737A19-0138-4DF2-BACC-2FF65E7E778C Q39093948-ABE5DA64-7A3D-4843-BB8C-58FBCFDBD1DB Q40051943-2BAEFCF0-BE69-49B4-8BF4-8F5A22075974

P2860

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

http://www.wikidata.org/entity/Q34785862

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@ast

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@en

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@nl

type

label

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@ast

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@en

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@nl

prefLabel

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@ast

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@en

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@nl

P1433

Q34785862-A12E4FDE-ADF2-46A6-A5BB-15A52EDA1FE6

P1476

Q34785862-3358B2C9-8EF2-4E3A-B0E1-45CB2F47E387

P2093

Q34785862-111047D4-9424-4F23-AEEB-5DA6BCA8FBDC

Q34785862-2076F40C-58F3-40F5-B8D9-A56C3980E8E4

Q34785862-477C02A8-0699-4D9F-9CBC-40F3F4211D7A

Q34785862-64331CC0-4D5B-4421-8D90-1F3254C6F9FC

Q34785862-6EDF2ED9-4B97-42D2-8B3B-BD8C39CD3E4B

Q34785862-85B3A22C-575B-4E34-8064-965DD3CFF3B8

Q34785862-9DD62694-8198-4F4D-890C-A68EBED8A625

Q34785862-B39552B7-2D14-411A-B5C7-D7B5EF34DCDF

Q34785862-BA6EAFBD-1D74-455A-9973-96C53DE53BA0

Q34785862-E37C6E16-FDCC-491C-9757-03A1EB5FDDA9

P2860

Q34785862-0769B166-F57C-45C6-AAB6-988452C3AFB1

Q34785862-0B6DA8C6-EF6A-4FCA-A510-4A1560AD38A3

Q34785862-147188FB-2B4F-46AE-9AA2-B35B5D580D28

Q34785862-266B7990-A737-4666-A58A-5D59CF32334D

Q34785862-2D8E0B70-3F2D-4E9A-A950-44384AFEFEE8

Q34785862-2F1CE31E-D62C-46A1-96C8-3686BABE96D4

Q34785862-47A02C0F-E269-4DA6-B914-68DE9BFB93BB

Q34785862-57823300-C1CB-4553-A8AC-1965D4240BF8

Q34785862-6ACB3F66-2C5A-4D52-A1E1-1EE28520D21D

Q34785862-6EB03A51-A5EA-40D2-B19D-A8BFEDE31016

P2888

Q34785862-8574CF64-FD59-44B6-B77D-C79A6DFC4E28

P304

Q34785862-0E6DC11A-F10A-4B50-8911-A7D57F35C9CF

P31

Q34785862-3C5698FD-C30A-47A5-94AA-7655D0246FA3

P356

Q34785862-67C8B938-8C70-4E6B-9720-C820362BD0A8

P407

Q34785862-53003102-7DC3-420E-9A3C-81377D3D871D

P433

Q34785862-D9FEC8B0-EAC7-46BB-A21F-7178281A8D1C

P478

Q34785862-6F7E0B94-CF80-48CD-968E-5BB7AA891D7E

P50

Q34785862-0CF46F7F-8297-4B40-B8E9-A6D38945EEC4

Q34785862-1B377B12-4BA3-48C8-85D0-E9F613869BBC

Q34785862-7F0E5961-5053-43FC-A339-2F8782F5FEB8

Q34785862-812401DC-AA3F-4A9B-B6F7-AB3076E86346

Q34785862-C857BBBB-E7F6-4047-8E1C-F6AE9D5B2966

Q34785862-CC10E56C-581A-49B0-9BB2-9EB58E7A08E0

Q34785862-D3C83912-61DC-419A-9116-1633446ABB1F

Q34785862-DD28BAE7-F7E4-4F03-897D-783308CAF2A4

P577

Q34785862-5578B2F5-14F0-4FBC-8269-09632831F856

P5875

Q34785862-7468AF7A-52EE-419C-84C1-1E078B33AB9C

P6179

Q34785862-B6F7166C-CE0E-40E5-AC1D-55E8A00F8967

P698

Q34785862-5E316A9A-C8E7-4E31-BA65-E9ACE558B1DC

P932

Q34785862-F243389F-FF55-4FA2-813B-FDB52F32AA8D

P356

P1433

Nature Communications

P1476

TM6SF2 rs58542926 influences h ...... alcoholic fatty liver disease.

@en

P2093

Anne-Christine Piguet

http://www.w3.org/2001/XMLSchema#string

Christopher P Day

http://www.w3.org/2001/XMLSchema#string

Dina Tiniakos

http://www.w3.org/2001/XMLSchema#string

Graeme J Alexander

http://www.w3.org/2001/XMLSchema#string

Helen L Reeves

http://www.w3.org/2001/XMLSchema#string

Julian B S Leathart

http://www.w3.org/2001/XMLSchema#string

Karine Clement

http://www.w3.org/2001/XMLSchema#string

Luc Van Gaal

http://www.w3.org/2001/XMLSchema#string

Peter Donaldson

http://www.w3.org/2001/XMLSchema#string

Sven Francque

http://www.w3.org/2001/XMLSchema#string

P2860

Biological, clinical and population relevance of 95 loci for blood lipids

Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans

PLINK: a tool set for whole-genome association and population-based linkage analyses

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease

Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.

Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

Genetic mapping in human disease

P2888

P304

4309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS5309

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Alastair D. Burt

Guruprasad P. Aithal

Quentin M Anstee

Michael Allison

Jean-François Dufour

Stuart McPherson

P577

2014-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263514576

http://www.w3.org/2001/XMLSchema#string

P6179

1013550200

http://www.w3.org/2001/XMLSchema#string

P698

24978903

http://www.w3.org/2001/XMLSchema#string

P932

4279183

http://www.w3.org/2001/XMLSchema#string